Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marie-Louise From Hermansen

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
BMJ Case Reports|March 3, 2021
Reactive arthritis after COVID-19Bo Langhoff Hønge, Marie-Louise From Hermansen, Merete Storgaard
Lupus|April 2, 2026
Real-world use of anifrolumab in systemic lupus erythematosus: A retrospective study from a Danish tertiary center (2022-2025)Laura Nørgaard, Mads Lamm Larsen, Bent Deleuran, et al.
Rheumatology International|September 3, 2021
Local and systemic reactogenicity of COVID-19 vaccine BNT162b2 in patients with systemic lupus erythematosus and rheumatoid arthritisLars Erik Bartels, Christian Ammitzbøll, Jakob Bøgh Andersen, et al.
ACR Open Rheumatology|July 17, 2021
Impaired Antibody Response to the BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine in Patients With Systemic Lupus Erythematosus and Rheumatoid ArthritisChristian Ammitzbøll, Lars Erik Bartels, Jakob Bøgh Andersen, et al.
The Journal of Rheumatology|March 2, 2022
Time Since Rituximab Treatment Is Essential for Developing a Humoral Response to COVID-19 mRNA Vaccines in Patients With Rheumatic DiseasesAnne Troldborg, Marianne Kragh Thomsen, Lars Erik Bartels, et al.
Modern Rheumatology|July 21, 2022
COVID-19 vaccination in patients with rheumatic diseases leads to a high seroconversion rate and reduced self-imposed isolation and shielding behaviourChristian Ammitzbøll, Marianne Kragh Thomsen, Jakob Bøgh Andersen, et al.
Rheumatology (Oxford, England)|November 29, 2022
Rituximab-treated rheumatic patients: B cells predict seroconversion after COVID-19 boost or revaccination in initial vaccine non-respondersChristian Ammitzbøll, Marianne Kragh Thomsen, Jakob Bøgh Andersen, et al.
ACR Open Rheumatology|June 26, 2024
COVID-19 Vaccination Before Initiating Rituximab Treatment Induces Strong Serological Response in Autoimmune Rheumatic Disease, Reducing Post-Pandemic Concerns About the Impact of RituximabChristian Ammitzbøll, Marianne Kragh Thomsen, Lars Erik Bartels, et al.
Clinical and Experimental Rheumatology|October 25, 2023
Revaccination of patients with systemic lupus erythematosus or rheumatoid arthritis without an initial COVID-19 vaccine response elicits seroconversion in half of the patientsChristian Ammitzbøll, Marianne Kragh Thomsen, Jakob Bøgh Andersen, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
BMJ Case Reports|March 3, 2021
Reactive arthritis after COVID-19Bo Langhoff Hønge, Marie-Louise From Hermansen, Merete Storgaard
Lupus|April 2, 2026
Real-world use of anifrolumab in systemic lupus erythematosus: A retrospective study from a Danish tertiary center (2022-2025)Laura Nørgaard, Mads Lamm Larsen, Bent Deleuran, et al.
Rheumatology International|September 3, 2021
Local and systemic reactogenicity of COVID-19 vaccine BNT162b2 in patients with systemic lupus erythematosus and rheumatoid arthritisLars Erik Bartels, Christian Ammitzbøll, Jakob Bøgh Andersen, et al.
ACR Open Rheumatology|July 17, 2021
Impaired Antibody Response to the BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine in Patients With Systemic Lupus Erythematosus and Rheumatoid ArthritisChristian Ammitzbøll, Lars Erik Bartels, Jakob Bøgh Andersen, et al.
The Journal of Rheumatology|March 2, 2022
Time Since Rituximab Treatment Is Essential for Developing a Humoral Response to COVID-19 mRNA Vaccines in Patients With Rheumatic DiseasesAnne Troldborg, Marianne Kragh Thomsen, Lars Erik Bartels, et al.
Modern Rheumatology|July 21, 2022
COVID-19 vaccination in patients with rheumatic diseases leads to a high seroconversion rate and reduced self-imposed isolation and shielding behaviourChristian Ammitzbøll, Marianne Kragh Thomsen, Jakob Bøgh Andersen, et al.
Rheumatology (Oxford, England)|November 29, 2022
Rituximab-treated rheumatic patients: B cells predict seroconversion after COVID-19 boost or revaccination in initial vaccine non-respondersChristian Ammitzbøll, Marianne Kragh Thomsen, Jakob Bøgh Andersen, et al.
ACR Open Rheumatology|June 26, 2024
COVID-19 Vaccination Before Initiating Rituximab Treatment Induces Strong Serological Response in Autoimmune Rheumatic Disease, Reducing Post-Pandemic Concerns About the Impact of RituximabChristian Ammitzbøll, Marianne Kragh Thomsen, Lars Erik Bartels, et al.
Clinical and Experimental Rheumatology|October 25, 2023
Revaccination of patients with systemic lupus erythematosus or rheumatoid arthritis without an initial COVID-19 vaccine response elicits seroconversion in half of the patientsChristian Ammitzbøll, Marianne Kragh Thomsen, Jakob Bøgh Andersen, et al.
Pageof 1